Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics

The identification of heterozygous neomorphic isocitrate dehydrogenase (IDH) mutations across multiple cancer types including both solid and hematologic malignancies has revolutionized our understanding of oncogenesis in these malignancies and the potential for targeted therapeutics using small mole...

Descripción completa

Detalles Bibliográficos
Autores principales: Golub, Danielle, Iyengar, Nishanth, Dogra, Siddhant, Wong, Taylor, Bready, Devin, Tang, Karen, Modrek, Aram S., Placantonakis, Dimitris G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534082/
https://www.ncbi.nlm.nih.gov/pubmed/31165048
http://dx.doi.org/10.3389/fonc.2019.00417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534082/
https://www.ncbi.nlm.nih.gov/pubmed/31165048
http://dx.doi.org/10.3389/fonc.2019.00417

Ejemplares similares